JMCP Findings - Optimizing the Management of Inherited Blood Disorders Part 1

FINDINGS FROM THE AMCP MARKET INSIGHTS PROGRAM | January, 2023

Summary

Hemophilia, sickle cell disease (SCD), and beta thalassemia (β thal) are inherited blood disorders likely to see multiple significant novel therapies approved in the near future, including the possibility for partial or complete cures with gene therapies. Although these are rare blood disorders, the high cost of treatment is an important consideration for payers and employers in ensuring that potentially curative therapies are affordable and accessible to the patients who need them.

Read More

For more disease state research, view the Market Insights Program.

For more disease state research, view the Market Insights Program.